CARsgen Therapeutics (CRTHF) News Today $0.76 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock CRTHF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period CARsgen Therapeutics Announces 2025 Interim ResultsAugust 14, 2025 | prnewswire.comCARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPOJuly 13, 2025 | prnewswire.comCARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPAJune 25, 2025 | prnewswire.comCARsgen’s Satri-cel Shows Promising Phase II Results in Advanced Cancer TreatmentJune 1, 2025 | tipranks.comCARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual MeetingJune 1, 2025 | prnewswire.comCARsgen's Satri-cel Granted Priority Review by the NMPAMay 27, 2025 | prnewswire.comCARsgen's Satri-cel Abstract Available on ASCO WebsiteMay 22, 2025 | prnewswire.comCARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and EfficacyMay 11, 2025 | prnewswire.comCARsgen’s Satri-cel Research Accepted for ASCO 2025 PresentationMarch 30, 2025 | tipranks.comCARsgen Announced 2024 Annual ResultsMarch 18, 2025 | prnewswire.comCARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPAMarch 2, 2025 | prnewswire.comCARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune DiseaseFebruary 27, 2025 | prnewswire.comCARsgen Partners with Zhuhai SB Xinchuang to Boost CAR-T Cell Development in ChinaFebruary 26, 2025 | tipranks.comCARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland ChinaFebruary 25, 2025 | prnewswire.comCARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4February 9, 2025 | prnewswire.comCARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated TrialJanuary 20, 2025 | prnewswire.comCARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated TrialJanuary 13, 2025 | prnewswire.comCARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T TherapyDecember 31, 2024 | prnewswire.comCARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)December 30, 2024 | prnewswire.comUK Stocks-Factors to watch on March 22March 22, 2022 | financialpost.comF Get CARsgen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTHF and its competitors with MarketBeat's FREE daily newsletter. Email Address CRTHF Media Mentions By Week CRTHF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRTHF News Sentiment▼0.000.70▲Average Medical News Sentiment CRTHF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRTHF Articles This Week▼00▲CRTHF Articles Average Week Get CARsgen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTHF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 60 Degrees Pharmaceuticals News Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News BerGenBio ASA News BriaCell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:CRTHF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARsgen Therapeutics Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CARsgen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access